alexa Pharmacogenetics-Guided Dosing for Fluoropyrimidines in Cancer Chemotherapy

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Pharmacogenetics-Guided Dosing for Fluoropyrimidines in Cancer Chemotherapy

 Cancer is a leading cause of mortality worldwide. It is a group of diseases characterized by the uncontrolled growth and spread of abnormal cells with accumulated genetic alterations that promote cancerous initiation, development, growth, and metastasis [1,2]. According to estimates from the International Agency for Research on Cancer (IARC), there were 12.7 million new cancer cases in 2008 worldwide, of which 5.6 million occurred in developed countries and 7.1 million in developing countries [3]. The corresponding estimates for total cancer deaths in 2008 were 7.6 million (about 21,000 cancer deaths a day), 2.8 million in developed countries and 4.8 million in developing countries [3,4]. Worldwide, almost 32.5 million people diagnosed with cancer within the five years previously were alive at the end of 2012. Breast cancer is the most frequently diagnosed cancer and the leading cause of cancer death among females, accounting for 23% of the total cancer cases and 14% of the cancer deaths.

Citation: He ZX, Zhou SF (2014) Pharmacogenetics-Guided Dosing for Fluoropyrimidines in Cancer Chemotherapy. Adv Pharmacoepidemiol Drug Saf 3:e125. doi: 10.4172/2167-1052.1000e125

  • Share this page
  • Facebook
  • Twitter
  • LinkedIn
  • Google+
  • Pinterest
  • Blogger